An izenivetmab injection (Lenivia; Zoetis) for reducing pain associated with osteoarthritis (OA) in canines has been granted ...
Innovative zwitterionic polymer facilitates insulin absorption through the skin, offering a painless alternative to ...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. announced today that Eisai has completed the rolling submission of the Supplemental Biologics License Application (sBLA ...
Cytopoint injection costs vary based on the size of your dog but can run anywhere from $50 to $200 or more. Cytopoint is a long-lasting, injectable treatment for dogs suffering from itchy, inflamed ...
In early October 2025, Merck announced FDA approval for a subcutaneous version of Keytruda and shared positive Phase 3 trial outcomes for both Keytruda in several cancer types and Winrevair in ...
Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer’s Disease GlobeNewswire Oct. 7, 2025 04:30 314 ...
TOKYO/CAMBRIDGE - Eisai Co., Ltd. and Biogen Inc. (NASDAQ:BIIB), a prominent biotechnology company with a robust gross profit margin of 76.3% and strong financial health according to InvestingPro ...
New LEQEMBI Companion TM program launched to expand helpful resources for patients throughout the treatment journey, including Nurse Educators who can provide patients with injection training, and an ...
Compared with placebo, significantly greater proportions of patients treated with Tremfya achieved clinical remission and endoscopic improvement. HealthDay News — The US Food and Drug Administration ...
The US FDA has approved pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck), a subcutaneous version of the intravenous formulation of Keytruda, for adults and children aged 12 years ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA QLEX™ (pembrolizumab and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback